{
    "clinical_study": {
        "@rank": "78880", 
        "arm_group": {
            "arm_group_label": "PF-04449913 Treatment", 
            "arm_group_type": "Experimental", 
            "description": "Treatment will be administered on an outpatient basis. All patients will be treated with an oral dose PF-04449913 at 100 mg daily in 4-week cycles for a total of 4 cycles. Patients who demonstrate no evidence of progressive disease (i.e. stable disease or better) may continue on treatment until disease progression or loss of response, limiting toxicity, or death."
        }, 
        "brief_summary": {
            "textblock": "This study is being done to see how safe an investigational drug is and test how well it\n      will work to help people with refractory/relapsed myelodysplastic syndrome (MDS) or chronic\n      myelomonocytic leukemia (CMML).\n\n      The main purpose of this study is to see whether the participant's disease responds\n      favorably to the investigational drug, PF-04449913."
        }, 
        "brief_title": "Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS)", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Myelodysplastic Syndrome (MDS)", 
            "Chronic Myelomonocytic Leukemia (CMML)"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Myelomonocytic, Chronic", 
                "Myelodysplastic Syndromes", 
                "Preleukemia", 
                "Leukemia, Myelomonocytic, Acute"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Must have a pathologically confirmed diagnosis by World Health Organization (WHO)\n             Criteria of MDS, CMML, or acute myeloid leukemia (AML) (except acute promyelocytic\n             leukemia) with < 30% bone marrow blasts (RAEB-t by French American British criteria)\n\n          -  Hypomethylating agent (azacitidine and/or decitabine) failure, defined as lack of\n             response, disease progression, loss of response, or intolerance as deemed by the\n             study investigator\n\n          -  Adequate renal function, as evidenced by a serum creatinine \u2264 2 times the\n             institutional upper limit of normal\n\n          -  Adequate hepatic function, as evidenced by a serum bilirubin < 2 times the\n             institutional upper limit of normal and an aspartic transaminase (AST) and alanine\n             transaminase (ALT) < 2 times the institutional upper limit of normal. Indirect\n             hyperbilirubinemia due to Gilbert's disease or hemolysis is permitted.\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status \u2264 2\n\n          -  Women of child-bearing potential and men must agree to use adequate contraception\n             (hormonal or barrier method of birth control; abstinence) for the duration of study\n             participation. Should a woman become pregnant or suspect she is pregnant while\n             participating in this study, she should inform her treating physician immediately.\n\n          -  Ability to understand and the willingness to sign a written informed consent document\n\n        Exclusion Criteria:\n\n          -  Patients with a history of prior therapy with another investigational agent within 4\n             weeks of the first planned dose of PF-0444913\n\n          -  Patients may not be receiving any other investigational agents.\n\n          -  History of allergic reactions attributed to compounds of similar chemical or biologic\n             composition to PF-04449913\n\n          -  Prior therapy with another hedgehog inhibitor\n\n          -  Concurrent use of any other agent for MDS, CMML, or AML. Growth factor use with\n             epoetin, darbepoetin, or granulocyte colony-stimulating factor must be terminated at\n             least 2 weeks before initiation of study treatment.\n\n          -  Any uncontrolled concurrent illness that would, in the opinion of the investigator,\n             limit compliance with study requirements\n\n          -  Second malignancy requiring active therapy\n\n          -  A prolonged corrected QT interval (QTc) of \u2265480 ms interval on electrocardiogram\n\n          -  History of metastatic cancer diagnosed less than 2 years prior to the first planned\n             dose of PF-0444913\n\n          -  Uncontrolled concurrent illness including, but not limited to, ongoing or active\n             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac\n             arrhythmia, or psychiatric illness/social situations that would limit compliance with\n             study requirements\n\n          -  Pregnant women are excluded from this study because PF-04449913 is smoothened\n             inhibitor with the potential for teratogenic or abortifacient effects. Because there\n             is an unknown but potential risk for adverse events in nursing infants secondary to\n             treatment of the mother with PF-04449913. Breastfeeding should be discontinued if the\n             mother is treated with PF-04449913.\n\n          -  Patients with immune deficiency are at increased risk of lethal infections when\n             treated with marrow-suppressive therapy. Therefore, HIV-positive patients receiving\n             combination antiretroviral therapy are excluded from the study because of possible\n             pharmacokinetic interactions with PF-04449913."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "35", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01842646", 
            "org_study_id": "MCC-17302"
        }, 
        "intervention": {
            "arm_group_label": "PF-04449913 Treatment", 
            "description": "Patients will be enrolled according to a two-step study design. Twenty patients will be enrolled in the first stage. All patients will be given a daily oral dose of PF-0444913 100 mg for up to 4 cycles, with an optional continuation phase. Dose escalation to 200 mg will be provided for patients who do not have at least hematologic improvement following 2 cycles, and dose reduction to 50 mg will be permitted for patients with significant toxicity. If at least 2 patients respond in the initial stage, and additional 15 patients will be enrolled in the second stage.", 
            "intervention_name": "PF-04449913", 
            "intervention_type": "Drug", 
            "other_name": [
                "Oral Hedgehog Inhibitor", 
                "Smo Inhibitor"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Leukemia", 
            "Myeloid Malignancies"
        ], 
        "lastchanged_date": "February 14, 2014", 
        "link": {
            "description": "Moffitt Cancer Center Clinical Trials website", 
            "url": "http://www.moffitt.org/research--clinical-trials/clinical-trials"
        }, 
        "location": {
            "contact": {
                "email": "lisa.nardelli@moffitt.org", 
                "last_name": "Lisa Nardelli", 
                "phone": "813-745-4731"
            }, 
            "facility": {
                "address": {
                    "city": "Tampa", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "33612"
                }, 
                "name": "H. Lee Moffitt Cancer Center and Research Institute"
            }, 
            "investigator": [
                {
                    "last_name": "Jeffrey Lancet, M.D.", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Rami Komrokji, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Alan List, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Eric Padron, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Bijal Shah, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Timothy Kubal, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Kendra Sweet, M.D.", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II Study Evaluating the Oral Smoothened Inhibitor PF-04449913 in Patients With Myelodysplastic Syndrome (MDS)", 
        "overall_official": {
            "affiliation": "H. Lee Moffitt Cancer Center and Research Institute", 
            "last_name": "Jeffrey Lancet, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Assessment of response by bone marrow biopsy and aspirate will be performed at weeks 9 and 17 according to International Working Group 2006 criteria as outlined below. The primary endpoint is best response on study, recorded from the start of the treatment until disease progression/recurrence. All responses must last for at least 8 weeks.  Complete Remission (CR): Bone marrow: \u2264 5% myeloblasts with normal maturation of all cell lines, Persistent dysplasia will be noted, Peripheral blood: Hemoglobin \u2265 11 g/dL, Platelets \u2265 100 x 10^9/L, Neutrophils \u2265 1.0 x 10^9/L, Blasts 0% ; Partial Remission (PR): All CR criteria if abnormal before treatment, except: Bone marrow blasts decreased by \u2265 50% over pretreatment but still > 5%, Cellularity and morphology not relevant; Marrow CR or Hematological Improvement (HI): Bone marrow: \u2264 5% myeloblasts and decrease by \u2265 50% over pretreatment Peripheral blood: if HI responses, they will be noted in addition to marrow CR.", 
            "measure": "Overall Response Rate (ORR)", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01842646"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To estimate the overall survival of patients with refractory/relapsed myelodysplastic Syndrome (MDS) and chronic myelo-monocytic leukemia (CMML) treated with PF-0444913. Overall survival will be defined as the time period between the date of the first dose of drug until the time of death.", 
                "measure": "Number of Participants with Overall Survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "To estimate the event-free survival of patients of this population. Event-free survival will be defined as the date of the first dose of study drug until failure or death from any cause.", 
                "measure": "Number of Participants with Event Free Survival", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "To estimate the time to transformation to AML in patients with <20% blasts. In patients with less than 20% blasts, the time to transformation to AML will be defined as the date of the first dose of drug until either the percentage of bone marrow blasts or the percentage of peripheral blasts exceeds 20%, whichever is first.", 
                "measure": "Median Time to Transformation to Acute Myeloid Leukemia (AML)", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "To evaluate the safety of PF-0444913 in this patient population. Toxicity will be scored using Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 for toxicity and adverse event reporting.", 
                "measure": "Number of Participants with Study Related Serious Adverse Events (SAEs)", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }
        ], 
        "source": "H. Lee Moffitt Cancer Center and Research Institute", 
        "sponsors": {
            "collaborator": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "H. Lee Moffitt Cancer Center and Research Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}